Baxter (BAX) traded lower Friday (March 27, 2026), extending recent weakness as the market continues to digest the company’s muted 2026 earnings setup and the operational/margin overhangs management outlined with its latest results and outlook. The selling pressure appears driven more by ongoing estimate resets and risk aversion than by a single new corporate headline.

Baxter’s latest outlook framed 2026 as a transition year, with adjusted EPS guided to $1.85–$2.05 and sales expected to be roughly flat, a combination that reinforced concerns about earnings power and pace of margin recovery. Management also highlighted tariffs as a significant 2026 headwind (about $130–$140 million), alongside manufacturing and mix pressures that have weighed on profitability and made improvement more back-half weighted.

Investors have also kept attention on the company’s infusion platform disruptions, including the voluntary pause on shipments and planned installations of the Novum infusion pump platform that has been expected to remain a constraint. Even if the direct revenue impact is manageable, the issue has contributed to a perception of execution risk at a time when the company is trying to stabilize margins and rebuild confidence.

Near-term, the key catalysts are any signs of improving gross margin trend, incremental cost/tariff mitigation actions, and clearer timelines around the infusion pump situation. With the stock trading near depressed levels, any update that de-risks 2026 earnings (or, conversely, signals further delays/costs) could drive outsized moves.